I disagree. If you don't think the trial (i.e., the scientific process for validating the scientific validity of the drug) is relevant to the current price or the valuation potential, then you're being led by your emotions regarding management. Trial results, which are entirely scientific in nature, can make or break this company. If you believe in the science, and thus that the results will bear that out in impressive fashion, then you'd be hard-pressed to say how management could squander a golden ticket. That they bungle the lead up to it (as they have done), then sure. But to assert that the ticket itself won't be gold, that I cannot agree with. Management may lie, but numbers, once released, can't.
News 
Market Data 
Discover 
